Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s durvalumab, a human monoclonal antibody directed against programmed death-ligand 1, in combination with SNDX-6352, Syndax’s monoclonal antibody inhibitor of Colony-StimulatingFactor 1 Receptor, across a variety of solid tumors.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
